Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR3 | P46089 | 1/20 | 0.40 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 4/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.36 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.33 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | PMM2 | O15305 | 1/20 | 0.32 |
| ▸ | G6PD | P11413 | 1/20 | 0.32 |
| ▸ | MPI | P34949 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 4/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | HTT | P42858 | 2/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL767077 | 0.76 | GPR3 (0.40) | GPR3CYP2A6CYP1A2MCL1KDM4E | |
| SCHEMBL317826 | 0.73 | GPR3 (0.42) | GPR3CYP2A6KDM4EEPAS1ALDH1A1 | |
| SCHEMBL65944 | 0.71 | GPR3 (0.40) | GPR3CYP2A6KDM4EEPAS1ALDH1A1 | |
| SCHEMBL66184 | 0.71 | GPR3 (0.40) | GPR3CYP2A6CYP1A2KDM4EEPAS1 | |
| SCHEMBL705050 | 0.71 | HSD17B10 (0.40) | CYP2A6CYP1A2ALDH1A1MAPTLMNA | |
| SCHEMBL3136356 | 0.71 | GPR3 (0.36) | GPR3LOXL2CYP2A6CASP3KMT2A | |
| SCHEMBL147923 | 0.70 | BCKDK (0.41) | ALDH1A1PMM2G6PDMPIMAPT | |
| SCHEMBL884398 | 0.70 | MPI (0.38) | ALDH1A1PMM2G6PDMPIMAPT | |
| SCHEMBL3529744 | 0.69 | GPR3 (0.33) | GPR3 | |
| SCHEMBL577481 | 0.68 | MAPK1 (0.38) | CYP2A6CYP1A2MCL1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 529 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190070149-A1 | PRIMARY AMINES AND DERIVATIVES THEREOF AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2019-03-07 | — | — | US | claimed |
| US-20170273954-A1 | METHODS AND COMPOSITIONS FOR BACTERIA INFECTIONS | THE UNIVERSITY OF CHICAGO (US) | 2017-09-28 | — | — | US | claimed |
| US-9675592-B2 | Methods and compositions for bacteria infections | THE UNIVERSITY OF CHICAGO (US) | 2017-06-13 | — | — | US | claimed |
| EP-2803358-B1 | 10,10-Dialkyl prostanoic acid derivatives as agents for lowering intraocular pressure | ALLERGAN INC (US) | 2017-05-03 | — | — | EP | claimed |
| US-20160120852-A1 | METHODS AND COMPOSITIONS FOR BACTERIA INFECTIONS | THE BOARD OF REGENTS OF THE UNIVERSITY OF ILLINOIS (US) | 2016-05-05 | — | — | US | claimed |
| US-9328107-B2 | Primary amines and derivatives thereof as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2016-05-03 | — | — | US | claimed |
| EP-2969003-A1 | METHODS AND COMPOSITIONS FOR BACTERIA INFECTIONS | The University of Chicago (US) | 2016-01-20 | — | — | EP | claimed |
| US-9156810-B2 | Treatment of inflammatory bowel disease | ALLERGAN, INC. (US) | 2015-10-13 | — | — | US | claimed |
| EP-2018371-B1 | PRIMARY AMINES AND DERIVATIVES THEREOF AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARM INC (US) | 2015-03-04 | — | — | EP | claimed |
| EP-2803358-A1 | 10,10-Dialkyl prostanoic acid derivatives as agents for lowering intraocular pressure | ALLERGAN, INC. (US) | 2014-11-19 | — | — | EP | claimed |
| EP-1066263-A1 | NOVEL CATIONIC 2-ACYLAMINOPHENOLS, THEIR USE AS COUPLER FOR OXIDATION DYEING, COMPOSITIONS CONTAINING THEM, AND DYEING METHODS | L'OREAL (FR) | 2001-01-10 | — | — | EP | claimed |
| WO-2000042971-A2 | NOVEL CATIONIC 2-SULPHONYLAMINOPHENOLS, THEIR USE AS COUPLERS FOR OXIDATION DYEING, COMPOSITIONS CONTAINING THEM AND DYEING METHODS | L'OREAL (FR) | 2000-07-27 | — | — | WO | claimed |
| WO-2000043368-A1 | NOVEL CATIONIC 2-ACYLAMINOPHENOLS, THEIR USE AS COUPLER FOR OXIDATION DYEING, COMPOSITIONS CONTAINING THEM, AND DYEING METHODS | L'OREAL (FR) | 2000-07-27 | — | — | WO | claimed |
| WO-2000042979-A1 | COMPOSITIONS FOR OXIDATION DYEING KERATIN FIBRES COMPRISING A CATIONIC COUPLER, NOVEL CATIONIC COUPLERS, THEIR USE FOR OXIDATION DYEING AND DYEING METHODS | L'OREAL (FR) | 2000-07-27 | — | — | WO | claimed |
| WO-2000043356-A1 | NOVEL CATIONIC COUPLERS AND THEIR USE FOR OXIDATION DYEING | L'OREAL (FR) | 2000-07-27 | — | — | WO | claimed |
| EP-1006110-A1 | DERIVATIVES OF ACYL-PIPERAZINIL-PYRIMIDINS, PREPARATION THEREOF AND APPLICATION AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2000-06-07 | — | — | EP | claimed |
| WO-1999067221-A1 | COMPOUNDS FOR INHIBITING BETA-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS | ELAN PHARMACEUTICALS, INC. (US) | 1999-12-29 | — | — | WO | claimed |
| US-5637592-A | TREATING HELICOBACTER INFECTIONS, SUCH AS GASTRITIS, STOMACH ULCERS, DUODENAL ULCERS AND GASTRIC CANCER | JANSSEN PHARMACEUTICA N.V. (BE) | 1997-06-10 | — | — | US | claimed |
| EP-0770074-A1 | ANTI-HELICOBACTER ACYL DERIVATIVES OF AZOLONES | JANSSEN PHARMACEUTICA N.V. (BE) | 1997-05-02 | — | — | EP | claimed |
| WO-1996001822-A1 | ANTI-HELICOBACTER ACYL DERIVATIVES OF AZOLONES | JANSSEN PHARMACEUTICA N.V. (BE) | 1996-01-25 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170273954-A1 | METHODS AND COMPOSITIONS FOR BACTERIA INFECTIONS | SPOUT1, OXA1L, VSIR | GPR3 3809/4885LOXL2 1515/4885CYP2A6 2557/4885 |
| US-20190070149-A1 | PRIMARY AMINES AND DERIVATIVES THEREOF AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | HTR5A, HTR2A, HTR1A | GPR3 415/4885LOXL2 1781/4885CYP2A6 496/4885 |
| US-20160120852-A1 | METHODS AND COMPOSITIONS FOR BACTERIA INFECTIONS | SPOUT1, OXA1L, VSIR | GPR3 3809/4885LOXL2 1515/4885CYP2A6 2557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.